Altre lingue Hybio Pharmaceutical Co., Ltd.

Azioni

300199

CNE1000011T7

Prezzo di chiusura Shenzhen S.E. Altri mercati azionari 00:00:00 09/07/2024			Variaz. 5gg	Var. 1 gen.
10,1 ^CNY	+0,70%		-6,39%	-25,63%

05/07	Hybio Pharmaceutical ottiene l'approvazione medica cilena per un farmaco iniettabile	MT
02/07	Il farmaco per le malattie ossee dell'unità Hybio Pharmaceutical ottiene l'autorizzazione alla commercializzazione in Cina	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Hybio Pharmaceutical Secures Chilean Medical Approval for Injectable Medication	05/07
Hybio Pharmaceutical Unit's Bone Disease Drug Gets China Marketing Nod	02/07
3SBIO Unit to Cooperate on Development, Sale of Weight Management Injection	29/05
Hybio Pharmaceutical Grants Commercial Rights of Weight Loss Drug to Sansheng Mandi Pharmaceutical	29/05
Hybio Pharmaceutical Gets Nod to Market Ganirelix Acetate Injection	28/05
Hybio Pharmaceutical Inks Cooperation Agreement With Zhongguancun Science City Management Committee	21/05
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26/04
Production Line of Hybio Pharma's Unit Passes Australian Regulator's Inspection	25/04
Hybio Pharmaceutical Gets Regulatory Nod to Test Weight Management Injection; Shares Up 5%	18/04
Hybio Pharmaceutical Gets Nod to Trial Semaglutide Injection; Shares Down 4%	06/12
Hybio Pharmaceutical Receives $14.1 Million Worth of Orders from US Company; Shares Up 6%	06/11
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23
Hybio Pharmaceutical Gets Nod to Trial COVID-19 Nasal Spray	21/09/23
Hybio Lands $30 Million Bulk Pharma Chemical Supply Deal With Overseas Client	21/09/23
Hybio Pharmaceutical Co., Ltd.(XSEC:300199) added to S&P Global BMI Index	18/09/23
Hybio Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14/08/23
Hybio Pharmaceutical Co., Ltd. announced that it expects to receive CNY 254.12 million in funding	11/08/23
Hybio Pharmaceutical Registers Acetic Acid Pharmaceutical Ingredient	12/07/23
Hybio Pharma’s Carboprost Injection Granted New Indication for Vaginal Delivery	11/07/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hybio Pharmaceutical Co., Ltd.

Azioni

300199

CNE1000011T7

Altre lingue

Filtri